clinical trial · NCT06480565
A Phase 1/2 Trial of ADI-270 in ccRCC
Clear Cell Renal Cell CarcinomaADI-270FludarabineCyclophosphamide
brief summary
This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
started
Dec 12, 2024
primary completion
Jun 1, 2026
completion
Jun 1, 2027
last updated
Aug 15, 2025
official title
A Phase 1/2 Trial of ADI-270 (Engineered γδ Chimeric Receptor [CAR] Vδ1 T Cells Targeting CD70) in Adults With Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol